If the release of CXCL13 could occur in vivo, it could promote the onset of B cell lymphomas, malignancies that indeed more frequently arise in patients suffering of IBD (Nissen et al., 2015). This evidence concerns the gene CXCL13 and inflammatory bowel disease.